Cambridge, MA, United States of America

Amylyx Pharmaceuticals Inc.

Calculating rank
USPTO Granted Patents = 11


Trademarks = 7

Forward Citations = 31

Loading Chart...
Loading Chart...

5 inventors (with patents filed for the assignee):

goldMedal Joshua Cohen (9 out of 9 patents)

silverMedal Justin Klee (9 out of 9 patents)

bronzeMedal David Wai Fung Ma (3 out of 3 patents)

4.  Xiaofeng Xiong (2 out of 8 patents)

5.  Debra Odink (2 out of 5 patents)

6.  Colleen M Craig (2 out of 12 patents)

7.  Christine Mn Smith (2 out of 2 patents)

8.  Tracey L Mclaughlin (2 out of 2 patents)

9.  Tracey L McLaughlin (10 patents)

10.  Christine MN Smith (0 patent)

11.  Joshua B Cohen (0 patent)


11 patents:

Company Overview
Amylyx Pharmaceuticals Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies for neurodegenerative diseases. The company specializes in advancing treatments that target the underlying mechanisms of conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Through its proprietary platform, Amylyx aims to address significant unmet medical needs, leveraging scientific expertise to improve patient outcomes and enhance quality of life for those affected by these challenging disorders.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 17 2026

11 Patents

#216 in Cambridge, MA

#1,663 in Massachusetts

#27,594 in US

#51,930 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America
Forward Citations = 31

5 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amylyx Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/amylyx-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…